S&P 500   3,138.06 (-0.25%)
DOW   27,927.82 (-0.31%)
QQQ   204.37 (-0.31%)
AAPL   267.06 (-1.35%)
FB   201.68 (+0.31%)
MSFT   151.40 (-0.23%)
GOOGL   1,346.10 (+0.50%)
AMZN   1,747.17 (-0.25%)
NVDA   212.30 (+0.06%)
MU   46.60 (-2.77%)
BABA   199.44 (-1.21%)
GE   11.02 (-0.72%)
TSLA   342.14 (+1.86%)
T   38.13 (-0.18%)
AMD   39.11 (-1.31%)
NFLX   302.98 (-1.42%)
BAC   33.55 (-0.36%)
DIS   145.66 (-1.35%)
S&P 500   3,138.06 (-0.25%)
DOW   27,927.82 (-0.31%)
QQQ   204.37 (-0.31%)
AAPL   267.06 (-1.35%)
FB   201.68 (+0.31%)
MSFT   151.40 (-0.23%)
GOOGL   1,346.10 (+0.50%)
AMZN   1,747.17 (-0.25%)
NVDA   212.30 (+0.06%)
MU   46.60 (-2.77%)
BABA   199.44 (-1.21%)
GE   11.02 (-0.72%)
TSLA   342.14 (+1.86%)
T   38.13 (-0.18%)
AMD   39.11 (-1.31%)
NFLX   302.98 (-1.42%)
BAC   33.55 (-0.36%)
DIS   145.66 (-1.35%)
S&P 500   3,138.06 (-0.25%)
DOW   27,927.82 (-0.31%)
QQQ   204.37 (-0.31%)
AAPL   267.06 (-1.35%)
FB   201.68 (+0.31%)
MSFT   151.40 (-0.23%)
GOOGL   1,346.10 (+0.50%)
AMZN   1,747.17 (-0.25%)
NVDA   212.30 (+0.06%)
MU   46.60 (-2.77%)
BABA   199.44 (-1.21%)
GE   11.02 (-0.72%)
TSLA   342.14 (+1.86%)
T   38.13 (-0.18%)
AMD   39.11 (-1.31%)
NFLX   302.98 (-1.42%)
BAC   33.55 (-0.36%)
DIS   145.66 (-1.35%)
S&P 500   3,138.06 (-0.25%)
DOW   27,927.82 (-0.31%)
QQQ   204.37 (-0.31%)
AAPL   267.06 (-1.35%)
FB   201.68 (+0.31%)
MSFT   151.40 (-0.23%)
GOOGL   1,346.10 (+0.50%)
AMZN   1,747.17 (-0.25%)
NVDA   212.30 (+0.06%)
MU   46.60 (-2.77%)
BABA   199.44 (-1.21%)
GE   11.02 (-0.72%)
TSLA   342.14 (+1.86%)
T   38.13 (-0.18%)
AMD   39.11 (-1.31%)
NFLX   302.98 (-1.42%)
BAC   33.55 (-0.36%)
DIS   145.66 (-1.35%)
Log in

NASDAQ:APVO - Aptevo Therapeutics Stock Price, Forecast & News

$0.61
+0.01 (+1.67 %)
(As of 12/9/2019 02:20 PM ET)
Today's Range
$0.61
Now: $0.61
$0.63
50-Day Range
$0.52
MA: $0.62
$0.70
52-Week Range
$0.49
Now: $0.61
$2.34
Volume2,400 shs
Average Volume277,786 shs
Market Capitalization$27.62 million
P/E RatioN/A
Dividend YieldN/A
Beta2.5
Aptevo Therapeutics Inc, a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:APVO
CUSIPN/A
Phone206-838-0500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$23.07 million
Book Value$1.33 per share

Profitability

Net Income$-53,690,000.00
Net Margins-156.03%

Miscellaneous

Employees118
Market Cap$27.62 million
Next Earnings Date3/16/2020 (Estimated)
OptionableOptionable

Receive APVO News and Ratings via Email

Sign-up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter.


Aptevo Therapeutics (NASDAQ:APVO) Frequently Asked Questions

What is Aptevo Therapeutics' stock symbol?

Aptevo Therapeutics trades on the NASDAQ under the ticker symbol "APVO."

How were Aptevo Therapeutics' earnings last quarter?

Aptevo Therapeutics Inc (NASDAQ:APVO) issued its earnings results on Thursday, November, 7th. The biotechnology company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.01. The biotechnology company earned $9.01 million during the quarter, compared to analysts' expectations of $8.05 million. Aptevo Therapeutics had a negative return on equity of 171.99% and a negative net margin of 156.03%. View Aptevo Therapeutics' Earnings History.

When is Aptevo Therapeutics' next earnings date?

Aptevo Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Aptevo Therapeutics.

What price target have analysts set for APVO?

2 brokerages have issued 12-month target prices for Aptevo Therapeutics' stock. Their forecasts range from $3.00 to $3.00. On average, they anticipate Aptevo Therapeutics' share price to reach $3.00 in the next twelve months. This suggests a possible upside of 391.8% from the stock's current price. View Analyst Price Targets for Aptevo Therapeutics.

What is the consensus analysts' recommendation for Aptevo Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptevo Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aptevo Therapeutics.

Has Aptevo Therapeutics been receiving favorable news coverage?

Media stories about APVO stock have been trending somewhat negative on Monday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aptevo Therapeutics earned a media sentiment score of -1.7 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Aptevo Therapeutics.

Are investors shorting Aptevo Therapeutics?

Aptevo Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totalling 1,770,000 shares, an increase of 48.7% from the October 31st total of 1,190,000 shares. Based on an average trading volume of 402,200 shares, the days-to-cover ratio is currently 4.4 days. Approximately 4.4% of the company's shares are sold short. View Aptevo Therapeutics' Current Options Chain.

Who are some of Aptevo Therapeutics' key competitors?

What other stocks do shareholders of Aptevo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptevo Therapeutics investors own include Synergy Pharmaceuticals (SGYP), Zynerba Pharmaceuticals (ZYNE), Advanced Micro Devices (AMD), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), NVIDIA (NVDA), Alibaba Group (BABA), Marinus Pharmaceuticals (MRNS), Micron Technology (MU) and AbbVie (ABBV).

Who are Aptevo Therapeutics' key executives?

Aptevo Therapeutics' management team includes the folowing people:
  • Mr. Marvin L. White, Pres, CEO & Director (Age 57)
  • Mr. Jeffrey G. Lamothe, Sr. VP, CFO & Treasurer (Age 53)
  • Dr. Scott C. Stromatt, Sr. VP of Clinical Devel. & Medical Affairs and Chief Medical Officer (Age 61)
  • Mr. Randy Joe Maddux, Sr. VP of Operations & Chief Manufacturing Officer (Age 58)
  • Dr. Jane A. Gross, Sr. VP & Chief Scientific Officer (Age 62)

Who are Aptevo Therapeutics' major shareholders?

Aptevo Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Point72 Asset Management L.P. (5.41%). Company insiders that own Aptevo Therapeutics stock include Barbara Lopez Kunz, Daniel Abdun-Nabi, Fuad El-Hibri, Grady Grant III, Marvin L White, Randy Joe Maddux and Zsolt Harsanyi. View Institutional Ownership Trends for Aptevo Therapeutics.

Which major investors are buying Aptevo Therapeutics stock?

APVO stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P.. Company insiders that have bought Aptevo Therapeutics stock in the last two years include Barbara Lopez Kunz, Daniel Abdun-Nabi, Fuad El-Hibri, Grady Grant III, Marvin L White, Randy Joe Maddux and Zsolt Harsanyi. View Insider Buying and Selling for Aptevo Therapeutics.

How do I buy shares of Aptevo Therapeutics?

Shares of APVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Aptevo Therapeutics' stock price today?

One share of APVO stock can currently be purchased for approximately $0.61.

How big of a company is Aptevo Therapeutics?

Aptevo Therapeutics has a market capitalization of $27.62 million and generates $23.07 million in revenue each year. The biotechnology company earns $-53,690,000.00 in net income (profit) each year or ($2.39) on an earnings per share basis. Aptevo Therapeutics employs 118 workers across the globe.View Additional Information About Aptevo Therapeutics.

What is Aptevo Therapeutics' official website?

The official website for Aptevo Therapeutics is http://www.aptevotherapeutics.com/.

How can I contact Aptevo Therapeutics?

Aptevo Therapeutics' mailing address is 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121. The biotechnology company can be reached via phone at 206-838-0500 or via email at [email protected]


MarketBeat Community Rating for Aptevo Therapeutics (NASDAQ APVO)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  151 (Vote Outperform)
Underperform Votes:  166 (Vote Underperform)
Total Votes:  317
MarketBeat's community ratings are surveys of what our community members think about Aptevo Therapeutics and other stocks. Vote "Outperform" if you believe APVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/9/2019 by MarketBeat.com Staff

Featured Article: What causes a recession?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel